摘要
目的:观察重组人血管内皮抑素(recombinant human endostatin,Endostar联合FOLFOX4方案治疗晚期结直肠癌(colon and rectal cancer,CRC)的临床疗效和不良反应。方法:将253例经病理组织学检查证实的晚期结直肠癌患者随机分为观察组和对照组,观察组126例,对照组127例。对照组给予FOLFOX4方案治疗,观察组采用重组人血管内皮抑素联合FOLFOX4方案治疗。比较两组近期疗效、生活质量和不良反应。结果:观察组与对照组总有效率(ORR)分别为60.32%和43.31%,两者比较差异有统计学意义(P=0.007);两组疾病控制率(DCR)分别为81.75%和70.87%,两者比较差异有统计学意义(P=0.042);首发CRC患者中,观察组与对照组的PR率比较差异有统计学意义(P=0.037);复发患者中,观察组与对照组的CR、PD、ORR和DCR率比较差异均有统计学意义(P=0.032;P=0.032;P=0.030;P=0.032);结论:利用重组人血管内皮抑素联合FOLFOX4方案治疗首发晚期结直肠癌患者,未能明显提高近期疗效;对于复发晚期患者,联合治疗优于单纯FOLFOX4方案治疗;联合治疗在提高生活质量方面与单纯化疗无明显差异;联合治疗无严重不良反应,安全性较好,具有潜在的临床应用前景。
Objective： To observe the effects of recombinant human endostatin （recombinant human endostatin, En- dostar） combined with FOLFOX4 regimen in the treatment of advanced node rectal cancer （colon and as cancer, CRC） of clini- cal efficacy and adverse reactions. Methods： 253 patients with advanced colorectal cancer were randomly divided into the obser- vation group and the control group, 126 cases in the observation group and 127 cases in the control group. The control group was treated with FOLFOX4, and the observation group was treated with recombinant human endostatin combined with FOL- FOX4 regimen. To compare the short--term efficacy, quality of life and adverse reactions of the two groups. Results： Total e{fective rate （ORR） of the observation group and the control group were 60.32 % and 43.31% respectively, the difference was statistically significant （P=0. 007） ; for two groups, the disease control rates （DCR） were 81.75% and 70.87% respectively, the difference was statistically significant （P=0. 042） ; the first CRC patients in the observation group and the control group, the PR rate was statistically significant （P=0. 037） ; relapse patients in the observation group and the control group CR, PD, ORR and DCR rates were statistically significant （P=0. 032; P=0. 032; P=0. 030; P=0. 032） ; Conclusion： The use of re- combinant human endostatin combined with FOLFOX4 regimen in the treatment of first--episode patients with advanced color- ectal cancer is not obvious to improve curative effect; for patients with advanced relapsed, combination therapy is better than pure FOLFOX4 treatment combination therapy in improving the quality of life and chemotherapy combined treatment had no significant difference; it has no serious adverse reaction, but has good safety and potential clinical application.
出处
《海南医学院学报》
CAS
2015年第8期1119-1122,共4页
Journal of Hainan Medical University
